BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » CAR-T » Page 2

History of CAR-T Cell Therapy Spans 60+ Years

March 13, 2020 By Cade Hildreth (CEO)

history of car-t cell

The groundbreaking approvals of two CAR-T therapies in 2017 was the climax of more than sixty years of devoted research. In the 1950s, the discovery of bone marrow transplantation laid the foundation for developing CAR-T therapy, as it was the first time that living cells were infused into blood cancer patients for the control of cancer.

As early as 1900s, researchers were becoming aware that T cells could easily search, recognize and kill cancer cells. To do this, the cells need a “guide” to direct them to the tumors, and thus, antibodies emerged as a valuable scientific and medical tool. [Read more…]

Filed Under: CAR-T Tagged With: CAR-T

Types of CAR-T Cells: Improvements in CAR Design and Construction

March 6, 2020 By Marie Carroll

Types of CAR-T Cells

What are the types of CAR-T cells and how have they changed in recent years? CAR-T cells are immune cells that are artificially engineered to express a particular chimeric antigen receptor (CAR), which have shown great potential in killing cancer cells. Chimeric antigen receptors (CARs) are artificially produced recombinant receptors having both antigen-binding and T-cell activating potentials.

CARs are composed of an extracellular recognition domain sourced from monoclonal antibodies (mAbs) and an intracellular signaling domain including CD3- and costimulatory domains for triggering endogenous signaling pathways of T-cells. [Read more…]

Filed Under: CAR-T Tagged With: CAR-T

Genetic Modification of CAR-T Cells

February 16, 2020 By Cade Hildreth (CEO)

genetic modification of CAR-T

Chimeric antigen receptor-modified T (CAR-T) cells are living therapies that are genetically engineered to express CAR molecules targeting antigens found on tumor cells or target cells of interest. Unfortunately, an obstacle for the field of CAR-T cell therapy is limited CAR T cell persistence after infusion into cancer patients. Thus, genetic engineering strategies to improve CAR T cell persistence will be central to the success of these gene-modified cellular therapies. [Read more…]

Filed Under: CAR-T Tagged With: CAR-T

INTELLiSTEM Announces the Launch of a New Antigen Identification Platform for the Development of Novel CAR T Cells

January 13, 2020 By Cade Hildreth (CEO)

Intellistem

TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy,  announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]

Filed Under: CAR-T, Press Releases Tagged With: CAR-T

CAR-T Cell Therapy Attracts Vast Sums of Money

December 5, 2019 By Cade Hildreth (CEO)

CAR T Cell Therapy

What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.

Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]

Filed Under: CAR-T, Cell Therapy Tagged With: CAR-T

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 7
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.